The Italian Competition Authority launches an investigation against pharmaceutical companies suspected of restricting drug sales (Roche / Novartis)

On February 6, 2013, the Italian Competition Authority ("ICA") launched a cartel investigation against Hoffmann-La Roche ("Roche"), Novartis, their respective Italian subsidiaries, and Genentec, a US company controlled by Roche and in which Novartis holds a 33% shareholding. The companies are suspected to have agreed to restrict the therapeutic applications of Avastin, a drug marketed by Roche, in order to advantage the sales of Lucentis, which is marketed by Novartis. Avastin is a drug patented by Genentech. It is treatment for patients with colon cancer, but it also cures certain ophtalmic diseases (i.e. wet age-related macular degeneration). However, the use of Avastin for the cure of ophthalmic diseases is possible only “off-label”, because Roche has not requested the

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Giovanni Scoccini, The Italian Competition Authority launches an investigation against pharmaceutical companies suspected of restricting drug sales (Roche / Novartis), 6 février 2013, e-Competitions February 2013, Art. N° 51809

Visites 469

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues